Anna M Czarnecka

List of Publications by Year in Descending Order

160 papers	2,389 citations	25 h-index	40 g-index
189 ext. papers	3,033 ext. citations	3.8 avg, IF	5.27 L-index

#	Paper	IF	Citations
160	Treatment of Locally Advanced Merkel Cell Carcinoma-A Multi-Center Study.. *Cancers*, **2022**, 14,	6.6	2
159	Efficacy of immunotherapy beyond RECIST progression in advanced melanoma: a real-world evidence.. *Cancer Immunology, Immunotherapy*, **2022**, 1	7.4	0
158	Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients. *Melanoma Research*, **2021**, 31, 49-57	3.3	0
157	First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland. *Immunotherapy*, **2021**, 13, 297-307	3.8	3
156	Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function. *Cancer Chemotherapy and Pharmacology*, **2021**, 87, 723-742	3.5	2
155	Biological Heterogeneity of Chondrosarcoma: From (Epi) Genetics through Stemness and Deregulated Signaling to Immunophenotype. *Cancers*, **2021**, 13,	6.6	2
154	Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	5
153	Chondrosarcoma-from Molecular Pathology to Novel Therapies. *Cancers*, **2021**, 13,	6.6	8
152	Feasibility and Long-Term Efficacy of PEComa Treatment-20 Years of Experience. *Journal of Clinical Medicine*, **2021**, 10,	5.1	4
151	Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma. *Journal of Dermatological Treatment*, **2021**, 1-7	2.8	0
150	Hyperpolarized 13C tracers: Technical advancements and perspectives for clinical applications. *Biocybernetics and Biomedical Engineering*, **2021**, 41, 1466-1466	5.7	1
149	Treatment beyond progression with immune checkpoint inhibitors in advanced melanoma.. *Journal of Clinical Oncology*, **2021**, 39, e21541-e21541	2.2	
148	Systemic treatment of patients with inoperable and metastatic Merkel cell carcinoma: A multicenter study.. *Journal of Clinical Oncology*, **2021**, 39, e21521-e21521	2.2	
147	Comparison of the efficacy and toxicity of anti-PD-1 monoclonal antibodies (nivolumab versus pembrolizumab) in treatment of patients with metastatic melanoma.. *Journal of Clinical Oncology*, **2021**, 39, e21514-e21514	2.2	0
146	Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	6
145	Endoglin Expression and Microvessel Density as Prognostic Factors in Pediatric Rhabdomyosarcoma. *Journal of Clinical Medicine*, **2021**, 10,	5.1	1
144	Radiotherapy in the Management of Pediatric and Adult Osteosarcomas: A Multi-Institutional Cohort Analysis. *Cells*, **2021**, 10,	7.9	1

143	The Management of Radiation-Induced Sarcomas: A Cohort Analysis from a Sarcoma Tertiary Center. *Journal of Clinical Medicine*, **2021**, 10,	5.1	2
142	Combined Preoperative Hypofractionated Radiotherapy With Doxorubicin-Ifosfamide Chemotherapy in Marginally Resectable Soft Tissue Sarcomas: Results of a Phase 2 Clinical Trial. *International Journal of Radiation Oncology Biology Physics*, **2021**, 110, 1053-1063	4	3
141	TP53 in Biology and Treatment of Osteosarcoma. *Cancers*, **2021**, 13,	6.6	5
140	Efficacy of Sirolimus Treatment in PEComa-10 Years of Practice Perspective. *Journal of Clinical Medicine*, **2021**, 10,	5.1	2
139	What is the best front-line approach in patients with desmoid fibromatosis? - A retrospective analysis from a reference center. *European Journal of Surgical Oncology*, **2021**, 47, 2602-2608	3.6	0
138	Mechanisms of Resistance to Targeted Therapies in Skin Cancers **2021**, 357-384		
137	Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence. *Advances in Medical Sciences*, **2020**, 65, 316-323	2.8	6
136	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. *Cancer*, **2020**, 126, 2637-2647	6.4	31
135	TP53-Deficient Angiosarcoma Expression Profiling in Rat Model. *Cancers*, **2020**, 12,	6.6	2
134	Targeted Therapy in Melanoma and Mechanisms of Resistance. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	35
133	Choosing The Right Animal Model for Renal Cancer Research. *Translational Oncology*, **2020**, 13, 100745	4.9	19
132	Renal carcinoma CD105-/CD44- cells display stem-like properties in vitro and form aggressive tumors in vivo. *Scientific Reports*, **2020**, 10, 5379	4.9	8
131	Mutation profile of primary subungual melanomas in Caucasians. *Oncotarget*, **2020**, 11, 2404-2413	3.3	4
130	Systemic Treatment for Advanced and Metastatic Malignant Peripheral Nerve Sheath Tumors-A Sarcoma Reference Center Experience. *Journal of Clinical Medicine*, **2020**, 9,	5.1	3
129	Diagnosis and treatment of malignant PEComa tumours **2020**, 16, 22-33		8
128	Rozpoznanie i leczenie nowotworów typu angiomyolipoma (AML) **2020**, 16, 116-132		2
127	Correlation of immunity-related adverse events with survival and response to anti-PD-1 treatment in patients with metastatic melanoma.. *Journal of Clinical Oncology*, **2020**, 38, e15164-e15164	2.2	
126	Prognostic and predictive factors for the outcomes of clear cell sarcoma (CCS) multidisciplinary treatment: The role of lymph node involvement.. *Journal of Clinical Oncology*, **2020**, 38, e23554-e23554	2.2	

125	Malignant peripheral nerve sheath tumors - Outcomes and prognostic factors based on the reference center experience. *Surgical Oncology*, **2020**, 35, 276-284	2.5	1
124	Epithelioid Sarcoma-From Genetics to Clinical Practice. *Cancers*, **2020**, 12,	6.6	11
123	Neoadjuvant Treatment Options in Soft Tissue Sarcomas. *Cancers*, **2020**, 12,	6.6	5
122	Molecular Biology of Osteosarcoma. *Cancers*, **2020**, 12,	6.6	94
121	Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy. *Cancers*, **2020**, 12,	6.6	7
120	Clinicopathological Features and Prognostic Factors of Primary Acral Melanomas in Caucasians. *Journal of Clinical Medicine*, **2020**, 9,	5.1	4
119	BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma. *Melanoma Research*, **2020**, 30, 465-471	3.3	7
118	Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. *Cancer*, **2020**, 126, 98-104	6.4	14
117	An update on the safety of nivolumab for the treatment of advanced melanoma. *Expert Opinion on Drug Safety*, **2020**, 19, 409-421	4.1	4
116	OC-0069 5x5 Gy with chemotherapy in borderline resectable soft tissue sarcomas: early results of a trial. *Radiotherapy and Oncology*, **2019**, 133, S31-S32	5.3	5
115	Metastatic renal cell carcinoma cells growing in 3D on poly-D-lysine or laminin present a stem-like phenotype and drug resistance. *Oncology Reports*, **2019**, 42, 1878-1892	3.5	5
114	Metastatic Tumor Burden and Loci as Predictors of First Line Sunitinib Treatment Efficacy in Patients with Renal Cell Carcinoma. *Scientific Reports*, **2019**, 9, 7754	4.9	3
113	Insulin and insulin-like growth factors act as renal cell cancer intratumoral regulators. *Journal of Cell Communication and Signaling*, **2019**, 13, 381-394	5.2	15
112	Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in patients with advanced gastrointestinal stromal tumors treated with sunitinib after imatinib failure. *Oncology Letters*, **2019**, 18, 3373-3380	2.6	2
111	Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities. *Nature Reviews Urology*, **2019**, 16, 655-673	5.5	12
110	Molecular biology of sarcoma **2019**, 14, 307-330		3
109	Malignant peripheral nerve sheath tumour (MPNST) **2019**, 14, 364-376		2
108	Mucosal melanoma □linical presentation and treatment based on a case series **2019**, 15, 223-230		2

107	Clinicopathological prognostic and predictive factors of malignant peripheral nerve sheath tumors (MPNST) survival and treatment efficacy.. *Journal of Clinical Oncology*, **2019**, 37, e22537-e22537	2.2	
106	Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice. *Targeted Oncology*, **2019**, 14, 729-742	5	9
105	Persistent Overexposure to N-Methyl-D-Aspartate (NMDA) Calcium-Dependently Downregulates Glutamine Synthetase, Aquaporin 4, and Kir4.1 Channel in Mouse Cortical Astrocytes. *Neurotoxicity Research*, **2019**, 35, 271-280	4.3	18
104	Development of extracellular matrix supported 3D culture of renal cancer cells and renal cancer stem cells. *Cytotechnology*, **2019**, 71, 149-163	2.2	13
103	Culture in embryonic kidney serum and xeno-free media as renal cell carcinoma and renal cell carcinoma cancer stem cells research model. *Cytotechnology*, **2018**, 70, 761-782	2.2	3
102	Effect of Everolimus on Heterogenous Renal Cancer Cells Populations Including Renal Cancer Stem Cells. *Stem Cell Reviews and Reports*, **2018**, 14, 385-397	6.4	3
101	Treatment outcomes in older patients with advanced gastrointestinal stromal tumor (GIST). *Journal of Geriatric Oncology*, **2018**, 9, 520-525	3.6	6
100	Three-Dimensional Cell Culture Model Utilization in Renal Carcinoma Cancer Stem Cell Research. *Methods in Molecular Biology*, **2018**, 1817, 47-66	1.4	9
99	Surface markers of cancer stem-like cells of ovarian cancer and their clinical relevance. *Wspolczesna Onkologia*, **2018**, 22, 48-55	1	24
98	Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinoma. *Medical Oncology*, **2018**, 35, 91	3.7	2
97	Involvement of the CB cannabinoid receptor in cell growth inhibition and G0/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212-2 in renal cell carcinoma. *BMC Cancer*, **2018**, 18, 583	4.8	26
96	Effects of cell-cell crosstalk on gene expression patterns in a cell model of renal cell carcinoma lung metastasis. *International Journal of Oncology*, **2018**, 52, 768-786	4.4	3
95	Doxorubicin plus dacarbazine (DoDa), doxorubicin plus ifosfamide (DI) or doxorubicin alone (Do) as first line treatment for advanced leiomyosarcoma (LMS): A retrospective study from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG).. *Journal of Clinical Oncology*, **2018**, 36, 11574-11574	2.2	6
94	Association of breathing patterns and quality of life in patients with nasal obstruction. *Otolaryngologia Polska*, **2018**, 72, 11-15	0.7	2
93	Cerebrovascular reactivity and cerebral perfusion of rats with acute liver failure: role of L-glutamine and asymmetric dimethylarginine in L-arginine-induced response. *Journal of Neurochemistry*, **2018**, 147, 692-704	6	2
92	High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors. *Melanoma Research*, **2018**, 28, 435-441	3.3	6
91	Colony, hanging drop, and methylcellulose three dimensional hypoxic growth optimization of renal cell carcinoma cell lines. *Cytotechnology*, **2017**, 69, 565-578	2.2	10
90	Immuno-oncology for renal cell carcinoma treatment: future perspectives for combinations and sequences with molecularly targeted agents. *Expert Opinion on Biological Therapy*, **2017**, 17, 151-162	5.4	4

89	Depressive-like neurochemical and behavioral markers of Parkinson's disease after 6-OHDA administered unilaterally to the rat medial forebrain bundle. *Pharmacological Reports*, **2017**, 69, 985-994	3.9	21
88	Renin angiotensin system deregulation as renal cancer risk factor. *Oncology Letters*, **2017**, 14, 5059-5068	2.6	26
87	Functional significance of CD105-positive cells in papillary renal cell carcinoma. *BMC Cancer*, **2017**, 17, 21	4.8	15
86	Cardiac safety of systemic therapy in breast cancer patients with high risk of atherosclerosis complications. *Future Oncology*, **2017**, 13, 593-602	3.6	4
85	The significance of rotational behavior and sensitivity of striatal dopamine receptors in hemiparkinsonian rats: A comparative study of lactacystin and 6-OHDA. *Neuroscience*, **2017**, 340, 308-318	3.9	9
84	Three-dimensional cell culture model utilization in cancer stem cell research. *Biological Reviews*, **2017**, 92, 1505-1520	13.5	72
83	Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma. *Future Oncology*, **2017**, 13, 31-49	3.6	15
82	Intracerebral Administration of S-Adenosylhomocysteine or S-Adenosylmethionine Attenuates the Increases in the Cortical Extracellular Levels of Dimethylarginines Without Affecting cGMP Level in Rats with Acute Liver Failure. *Neurotoxicity Research*, **2017**, 31, 99-108	4.3	8
81	Contribution of the nitric oxide donor molsidomine and the antiparkinsonian drug l-DOPA to the modulation of the blood pressure in unilaterally 6-OHDA-lesioned rats. *Pharmacological Reports*, **2017**, 69, 29-35	3.9	2
80	Asymmetric Dimethylarginine and Hepatic Encephalopathy: Cause, Effect or Association?. *Neurochemical Research*, **2017**, 42, 750-761	4.6	13
79	Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells. *Cell and Bioscience*, **2017**, 7, 71	9.8	18
78	Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient. *Frontiers in Pharmacology*, **2017**, 8, 329	5.6	5
77	Gene set enrichment analysis and ingenuity pathway analysis of metastatic clear cell renal cell carcinoma cell line. *American Journal of Physiology - Renal Physiology*, **2016**, 311, F424-36	4.3	17
76	Hormone signaling pathways as treatment targets in renal cell cancer (Review). *International Journal of Oncology*, **2016**, 48, 2221-35	4.4	21
75	Triiodothyronine regulates cell growth and survival in renal cell cancer. *International Journal of Oncology*, **2016**, 49, 1666-78	4.4	9
74	Choosing the right cell line for renal cell cancer research. *Molecular Cancer*, **2016**, 15, 83	42.1	129
73	Prolonged complete response following gemcitabine-erlotinib combined therapy in advanced pancreatic cancer. *Oncology Letters*, **2016**, 11, 1101-1104	2.6	8
72	Comparative Gene Expression Profiling of Primary and Metastatic Renal Cell Carcinoma Stem Cell-Like Cancer Cells. *PLoS ONE*, **2016**, 11, e0165718	3.7	23

71	Gene expression profiling of primary and metastatic renal cell carcinoma tumor initiating cells.. *Journal of Clinical Oncology*, **2016**, 34, e16091-e16091	2.2	
70	The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory. *Current Pharmaceutical Design*, **2016**, 22, 1756-66	3.3	29
69	Thyroid Hormones as Renal Cell Cancer Regulators. *Journal of Signal Transduction*, **2016**, 2016, 1362407		6
68	Insulin-like growth factor-1 signaling in renal cell carcinoma. *BMC Cancer*, **2016**, 16, 453	4.8	30
67	Management of pediatric head and neck rhabdomyosarcoma: A case-series of 36 patients. *Oncology Letters*, **2016**, 12, 3555-3562	2.6	11
66	Mechanisms through which diabetes mellitus influences renal cell carcinoma development and treatment: A review of the literature. *International Journal of Molecular Medicine*, **2016**, 38, 1887-1894	4.4	20
65	Chemotherapy of pancreatic solid pseudopapillary carcinoma □A case report and a literature review. *Cancer Treatment Communications*, **2016**, 7, 47-51		3
64	Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer. *Oncology Reports*, **2016**, 35, 1433-42	3.5	9
63	Future perspectives for mTOR inhibitors in renal cell cancer treatment. *Future Oncology*, **2015**, 11, 801-17	3.6	12
62	Long-term parental satisfaction with adenotonsillectomy: a population study. *Sleep and Breathing*, **2015**, 19, 1425-9	3.1	1
61	The preferential nNOS inhibitor 7-nitroindazole and the non-selective one N(G)-nitro-L-arginine methyl ester administered alone or jointly with L-DOPA differentially affect motor behavior and monoamine metabolism in sham-operated and 6-OHDA-lesioned rats. *Brain Research*, **2015**, 1625, 218-37	3.7	1
60	Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer. *Future Oncology*, **2015**, 11, 17-26	3.6	13
59	Interleukin-6 as an emerging regulator of renal cell cancer. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 476-85	2.8	38
58	Insulin and IGFs in renal cancer risk and progression. *Endocrine-Related Cancer*, **2015**, 22, R253-64	5.7	42
57	The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis. *Stem Cell Reviews and Reports*, **2015**, 11, 919-43	6.4	59
56	Obstructive sleep apnea and cancer: effects of intermittent hypoxia?. *Future Oncology*, **2015**, 11, 3285-98	3.6	12
55	Feasibility, efficacy and safety of tyrosine kinase inhibitor treatment in hemodialyzed patients with renal cell cancer: 10 years of experience. *Future Oncology*, **2015**, 11, 2267-82	3.6	22
54	The role of the cell-cell interactions in cancer progression. *Journal of Cellular and Molecular Medicine*, **2015**, 19, 283-96	5.6	60

53	Impaired glucose metabolism treatment and carcinogenesis. *Oncology Letters*, **2015**, 10, 589-594	2.6	4
52	The Role of Diabetes in Molecular Pathogenesis of Cancer. *Current Signal Transduction Therapy*, **2015**, 10, 10-16	0.8	1
51	Nasopharyngeal chordoma in a patient with a severe form of sleep-disordered breathing: A case report. *Oncology Letters*, **2015**, 10, 1805-1809	2.6	2
50	Rhabdomyosarcoma of the head and neck in children. *Wspolczesna Onkologia*, **2015**, 19, 98-107	1	20
49	Biology of renal tumour cancer stem cells applied in medicine. *Wspolczesna Onkologia*, **2015**, 19, A44-51	1	12
48	Current approaches in identification and isolation of human renal cell carcinoma cancer stem cells. *Stem Cell Research and Therapy*, **2015**, 6, 178	8.3	52
47	Molecular basis of carcinogenesis in diabetic patients (review). *International Journal of Oncology*, **2015**, 46, 1435-43	4.4	7
46	Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA. *Behavioural Brain Research*, **2015**, 283, 203-14	3.4	9
45	Snoring but not BMI influences aggressive behavior and concentration problems in children. *Otolaryngologia Polska*, **2015**, 69, 22-9	0.7	4
44	Molecular events regulating clear cell renal cell cancer resistance to tyrosine kinase inhibitors.. *Journal of Clinical Oncology*, **2015**, 33, e15600-e15600	2.2	
43	Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2014**, 1845, 31-41	11.2	54
42	Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra. *Behavioural Brain Research*, **2014**, 261, 79-88	3.4	17
41	Vitamin D receptor gene polymorphisms in breast and renal cancer: current state and future approaches (review). *International Journal of Oncology*, **2014**, 44, 349-63	4.4	30
40	Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma. *Current Signal Transduction Therapy*, **2014**, 8, 210-218	0.8	18
39	Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC). *Current Signal Transduction Therapy*, **2014**, 8, 218-228	0.8	56
38	Metastasis-Initiating Cells in Renal Cancer. *Current Signal Transduction Therapy*, **2014**, 8, 240-246	0.8	16
37	Clinical and molecular prognostic and predictive biomarkers in clear cell renal cell cancer. *Future Oncology*, **2014**, 10, 2493-508	3.6	7
36	The role of prostaglandin E2 in renal cell cancer development: future implications for prognosis and therapy. *Future Oncology*, **2014**, 10, 2177-87	3.6	14

35	The use of sunitinib in renal cell carcinoma: where are we now?. *Expert Review of Anticancer Therapy* , **2014**, 14, 983-99	3.5	6
34	Tracheal adenoid cystic carcinoma mimicking a thyroid tumor: A case report. *Oncology Letters*, **2014** , 8, 1312-1316	2.6	7
33	Frontiers in clinical and molecular diagnostics and staging of metastatic clear cell renal cell carcinoma. *Future Oncology*, **2014**, 10, 1095-111	3.6	27
32	Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma. *Frontiers in Oncology*, **2014**, 4, 194	5.3	18
31	Renal cell carcinoma with intramyocardial metastases. *BMC Urology*, **2014**, 14, 73	2.2	9
30	Renal Cell Carcinoma Cancer Stem Cells as Therapeutic Targets. *Current Signal Transduction Therapy* , **2014**, 8, 203-209	0.8	6
29	Treatment obstacles for metastatic clear cell renal cell carcinoma of Fuhrman grade IV and with sarcomatoid histologies.. *Journal of Clinical Oncology*, **2014**, 32, e15604-e15604	2.2	
28	Molecular factors regulating clear cell renal cancer cellsTfate: Implications for tyrosine kinase inhibitors responsiveness and toxicities.. *Journal of Clinical Oncology*, **2014**, 32, e15577-e15577	2.2	
27	The regulation of clear cell renal cancer cells proliferation and tyrosine kinase inhibitors responsiveness by tumor micro-environmental factors.. *Journal of Clinical Oncology*, **2014**, 32, 488-488	2.2	
26	Serum EPO and VEGF levels in patients with sleep-disordered breathing and acute myocardial infarction. *Sleep and Breathing*, **2013**, 17, 1063-9	3.1	5
25	Hsp60 and human aging: Les liaisons dangereuses. *Frontiers in Bioscience - Landmark*, **2013**, 18, 626-37	2.8	22
24	Ovarian cancer as a genetic disease. *Frontiers in Bioscience - Landmark*, **2013**, 18, 543-63	2.8	14
23	Alterations in the expression of nNOS in the substantia nigra and subthalamic nucleus of 6-OHDA-lesioned rats: the effects of chronic treatment with l-DOPA and the nitric oxide donor, molsidomine. *Brain Research*, **2013**, 1541, 92-105	3.7	16
22	Hsp10: anatomic distribution, functions, and involvement in human disease. *Frontiers in Bioscience - Elite*, **2013**, 5, 768-78	1.6	19
21	Vulvar cancer as a target for molecular medicine. *Frontiers in Bioscience - Scholar*, **2011**, 3, 136-44	2.4	4
20	Laryngeal embryonal rhabdomyosarcoma in an adult - a case presentation in the eyes of geneticists and clinicians. *BMC Cancer*, **2011**, 11, 166	4.8	11
19	(99m)TC-octreotide scintigraphy and somatostatin receptor subtype expression in juvenile nasopharyngeal angiofibromas. *Head and Neck*, **2011**, 33, 1739-46	4.2	11
18	The role of the mitochondrial genome in ageing and carcinogenesis. *Journal of Aging Research*, **2011**, 2011, 136435	2.3	25

17	Mitochondrial DNA mutations in cancer--from bench to bedside. *Frontiers in Bioscience - Landmark*, **2010**, 15, 437-60	2.8	21
16	Aggressive osteoblastoma of the sphenoid bone. *Oncology Letters*, **2010**, 1, 367-371	2.6	13
15	Mitochondrial genotype and breast cancer predisposition. *Oncology Reports*, **2010**, 24, 1521-34	3.5	16
14	Mitochondrial NADH-dehydrogenase subunit 3 (ND3) polymorphism (A10398G) and sporadic breast cancer in Poland. *Breast Cancer Research and Treatment*, **2010**, 121, 511-8	4.4	62
13	Molecular oncology focus - is carcinogenesis a Ţmitochondriopathy?. *Journal of Biomedical Science*, **2010**, 17, 31	13.3	17
12	Mitochondrial genotype in vulvar carcinoma - cuckoo in the nest. *Journal of Biomedical Science*, **2010**, 17, 73	13.3	11
11	Mitochondrial NADH-dehydrogenase polymorphisms as sporadic breast cancer risk factor. *Oncology Reports*, **2010**, 23, 531-5	3.5	16
10	Common mitochondrial polymorphisms as risk factor for endometrial cancer. *International Archive of Medicine*, **2009**, 2, 33		22
9	Breast cancer as a mitochondrial disorder (Review). *Oncology Reports*, **2009**, 21, 845-51	3.5	14
8	Mitochondrial DNA Mutations in Tumors **2009**, 119-130		1
7	Upon oxidative stress, the antiapoptotic Hsp60/procaspase-3 complex persists in mucoepidermoid carcinoma cells. *European Journal of Histochemistry*, **2008**, 52, 221-8	2.1	47
6	CD1a down-regulation in primary invasive ductal breast carcinoma may predict regional lymph node invasion and patient outcome. *Histopathology*, **2008**, 52, 203-12	7.3	22
5	Hsp60 and Hspl0 as antitumor molecular agents. *Cancer Biology and Therapy*, **2007**, 6, 487-9	4.6	29
4	Mitochondrial DNA mutations in human neoplasia. *Journal of Applied Genetics*, **2006**, 47, 67-78	2.5	62
3	Mitochondrial chaperones in cancer: from molecular biology to clinical diagnostics. *Cancer Biology and Therapy*, **2006**, 5, 714-20	4.6	116
2	Heat shock protein 10 and signal transduction: a "capsula eburnea" of carcinogenesis?. *Cell Stress and Chaperones*, **2006**, 11, 287-94	4	46
1	Balance between transcription and RNA degradation is vital for Saccharomyces cerevisiae mitochondria: reduced transcription rescues the phenotype of deficient RNA degradation. *Molecular Biology of the Cell*, **2006**, 17, 1184-93	3.5	34